Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Kwietniak Matthew R.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-669Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Kwietniak Matthew R.Ownership Type:Direct OwnershipSecurities:Common Stock, $0.001 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:669Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,251Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,261Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-696Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Common Stock, $0.001 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:1,251Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Common Stock, $0.001 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:1,261Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Common Stock, $0.001 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:696Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Richieri Richard A.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,060Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Richieri Richard A.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-946Price:--
Filings by filing date
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Kwietniak Matthew R.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-669Price:--
-
Apr 11, 2024 (filed on Apr 12, 2024)Insider Name:Kwietniak Matthew R.Ownership Type:Direct OwnershipSecurities:Common Stock, $0.001 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:669Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,251Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,261Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-696Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Common Stock, $0.001 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:1,251Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Common Stock, $0.001 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:1,261Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Ziebell Mark ROwnership Type:Direct OwnershipSecurities:Common Stock, $0.001 par valueNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:696Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Richieri Richard A.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,060Price:--
-
Apr 09, 2024 (filed on Apr 11, 2024)Insider Name:Richieri Richard A.Ownership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-946Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 14191 MYFORD ROAD TUSTIN CA 92780 |
Tel: | 1-415-6757401 |
Website: | https://avidbio.com |
IR: | See website |
Key People | ||
Nicholas Stewart Green President, Chief Executive Officer, Director | Daniel Ryan Hart Chief Financial Officer | Richard A. Richieri Chief Operations Officer |
Mark R. Ziebell Vice President, General Counsel, Corporate Secretary | Oksana Lukash Vice President - People | Pramthesh Patel Vice President - Process Development | Matthew Kwietniak Chief Commercial Officer |
Business Overview |
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Company's services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply. |
Financial Overview |
For the nine months ended 31 January 2024, Avid Bioservices Inc revenues decreased 11% to $96.9M. Net loss totaled $17.6M vs. income of $594K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Other decrease from $627K (income) to $1.8M (expense), Int exp on Financial Lease Liabilities increase from $96K to $200K (expense). |
Employees: | 365 as of Apr 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $584.42M as of Jan 31, 2024 |
Annual revenue (TTM): | $136.74M as of Jan 31, 2024 |
EBITDA (TTM): | -$6.34M as of Jan 31, 2024 |
Net annual income (TTM): | -$17.96M as of Jan 31, 2024 |
Free cash flow (TTM): | -$38.50M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | $119.61M as of Jan 31, 2024 |
Shares outstanding: | 63,479,794 as of Apr 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |